EU Scientists Rethink Cancer With Peptide Power

EU scientists target tumor scaffolding with peptides, aiming to boost cancer therapies through novel combination strategies

24 Dec 2025

In the crowded field of cancer research, attention is shifting from the tumour itself to what surrounds it. Across Europe, scientists are probing the tumour microenvironment, the dense web of proteins and cells that shields malignant growths from drugs and immune attack. An EU-backed project, ACT-MATRIX, is betting that this protective barrier may prove as important a target as the cancer cells within.

Funded by Horizon Europe, the initiative is developing small therapeutic peptides designed to disrupt the structural matrix around solid tumours. The work is still preclinical and focuses on ovarian cancer. Yet the logic, researchers argue, could apply to other solid tumours. Instead of killing malignant cells outright, the aim is to weaken their defences, making them more vulnerable to existing treatments.

At the centre of the effort is TAX2, a lead peptide candidate. In preclinical models it has slowed tumour growth and reduced metastatic spread. When combined with antibody-based therapies, it has shown stronger anti-tumour effects than either approach alone. Results reported on the EU’s CORDIS platform suggest that, if confirmed in human trials, such combinations could complement current standards of care.

The strategy reflects a broader shift in peptide science. Long associated with metabolic diseases and weight management, peptides are increasingly being recast as precise tools for complex conditions, including cancer. Targeting the tumour environment rather than the tumour alone may open new ways to design combination regimens, an approach already central to modern oncology.

Commercial interest is stirring. European manufacturers such as Bachem and PolyPeptide are expanding production capacity as global demand for peptide-based medicines grows. Should candidates like TAX2 advance to clinical stages, partnerships between research groups and industry are likely to follow.

Yet the obstacles are considerable. Tumour biology is intricate, and many promising preclinical findings fail in human trials. Regulators will demand robust evidence of safety and benefit. Competition in oncology is intense, and development timelines are long.

Even so, ACT-MATRIX signals confidence in Europe’s peptide ecosystem. If its scientific promise translates into clinical proof, dismantling tumours’ scaffolding may become a useful addition to cancer’s expanding toolkit.